Akero Therapeutics, Inc. (AKRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
AKRO Stock Price Chart Interactive Chart >
AKRO Price/Volume Stats
| Current price | $45.39 | 52-week high | $54.88 |
| Prev. close | $46.80 | 52-week low | $7.52 |
| Day low | $44.68 | Volume | 516,903 |
| Day high | $47.18 | Avg. volume | 597,612 |
| 50-day MA | $46.53 | Dividend yield | N/A |
| 200-day MA | $26.61 | Market Cap | 2.12B |
Akero Therapeutics, Inc. (AKRO) Company Bio
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
Latest AKRO News From Around the Web
Below are the latest news stories about AKERO THERAPEUTICS INC that investors may wish to consider to help them evaluate AKRO as an investment opportunity.
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial StrategySOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy. “Akero is thrilled to welcome Patrick to the team, especially following last year’s HARMONY study results, which further demonstrate EFX’s potential to treat |
The Akero Therapeutics Inc. (AKRO) had a good session last reading, didn’t it?The share price of Akero Therapeutics Inc. (NASDAQ:AKRO) fell to $44.49 per share on Wednesday from $49.49. While Akero Therapeutics Inc. has underperformed by -10.10%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AKRO rose by 105.02%, with highs and lows ranging from $54.88 to $7.52, […] |
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA. |
This Insider Just Sold Shares of Akero Therapeutics IncRelated Stocks: AKRO , |
Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH ProgramAkero Therapeutics Inc (NASDAQ: AKRO) completed enrollment of the Phase 2b SYMMETRY main study evaluating efruxifermin (EFX) for non-alcoholic steatohepatitis (NASH) in patients with compensated cirrhosis fibrosis stage 4 (F4). Enrollment is also complete for the expansion cohort, known as Cohort D, evaluating EFX in combination with GLP-1 therapy in patients with fibrosis stage 1-3 (F1-F3) and Type 2 Diabetes. One hundred eighty-two patients have been randomized to receive once-weekly subcutane |
AKRO Price Returns
| 1-mo | 1.27% |
| 3-mo | 17.90% |
| 6-mo | 258.81% |
| 1-year | 141.31% |
| 3-year | 73.97% |
| 5-year | N/A |
| YTD | -17.17% |
| 2022 | 159.10% |
| 2021 | -18.02% |
| 2020 | 16.24% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...